The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide

Biomaterials

Volumn 35, Issue 10, 2014, Pages 3396-3405

  Michiue, Hiroyuki ^a   Sakurai, Yoshinori ^b   Kondo, Natsuko ^b   Kitamatsu, Mizuki ^c   Bin, Feng ^d   Nakajima, Kiichiro ^e   Hirota, Yuki ^f   Kawabata, Shinji ^f   Nishiki, Tei ichi ^a   Ohmori, Iori ^a   Tomizawa, Kazuhito ^g   Miyatake, Shin ichi ^f   Ono, Koji ^b   Matsui, Hideki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e KNC Laboratories Co Ltd   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

BSH poly arginine; Oron neutron capture therapy (BNCT); Protein transduction; TAT

Indexed keywords

AMINO ACID TRANSPORTER; ANTI-CANCER THERAPIES; BORON NEUTRON CAPTURE THERAPY; BSH POLY-ARGININE; CELL-PENETRATING PEPTIDE; NEUTRON CAPTURE THERAPY; PROTEIN TRANSDUCTION; TAT;

AMINO ACIDS; BACTERIOPHAGES; BORON; CELL MEMBRANES; ENERGY TRANSFER; EXPERIMENTS; NEUTRON IRRADIATION; NEUTRONS; PATIENT TREATMENT; PEPTIDES; SYNTHESIS (CHEMICAL);

CYTOLOGY;

ANTINEOPLASTIC AGENT; BOROCAPTATE; CELL PENETRATING PEPTIDE;

ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY ASSAY; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; ENERGY TRANSFER; GLIOBLASTOMA; GLIOMA CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; JAPANESE; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; PRIORITY JOURNAL;

BSH POLY-ARGININE; ORON NEUTRON CAPTURE THERAPY (BNCT); PROTEIN TRANSDUCTION; TAT;

BOROHYDRIDES; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; PEPTIDES; SULFHYDRYL COMPOUNDS;

EID: 84893638298     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.055     Document Type: Article

References (48)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
2. Kawabata S., Miyatake S., Kuroiwa T., Yokoyama K., Doi A., Iida K., et al. boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res 2009, 50(1):51-60.
3. Locher G.L. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol 1936, 36:1-13.
4. Soloway A.H., Hatanaka H., Davis M.A. penetration of brain and brain tumor. VII. tumor- binding sulfhydryl boron compounds. J Med Chem 1967, 10:714-717.
5. Miyatake S., Tamura Y., Kawabata S., Iida K., Kuroiwa T., Ono K. boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 2007, 61(1):82-90.
6. Barth R.F. boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 2009, 67(7-8 Suppl.):S3-S6.
7. Hatanaka H. a revised boron-neutron capture therapy for malignant brain tumors. J Neurol 1975, 209:81-94.
8. Imahori Y., Ueda S., Ohmori Y., Kuzuki T., Ono K., Fujii R., et al. fluorine-18-Labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998, 39:325-333.
9. Nakamura H., Miyajima Y., Takei T., Kasaoka S., Maruyama K. synthesis and vesicle formation of a nido-carborane cluster lipid for boron neutron capture therapy. Chem Commun 2004, 1910-1911.
10. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., Matsui H. a high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J Neurosci 2001, 21(16):6000-6007.
11. 2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 2005, 280(9):8285-8289.
12. Michiue H., Tomizawa K., Matsushita M., Tamiya T., Lu Y.F., Ichikawa T., et al. ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 2005, 579(18):3965-3969.
13. Matsui H., Tomizawa K., Lu Y.F., Matsushita M. protein therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci 2003, 4(2):151-157.
14. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., et al. transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998, 4(12):1449-1452.
15. Michiue H., Eguchi A., Scadeng M., Dowdy S.F. induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 2009, 8(23):2306-2313.
16. Gump J.M., Dowdy S.F. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007, 13(10):443-448.
17. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004, 10(3):310-315.
18. Kobayashi T., Kanda K. analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat Res 1982, 91:77-94.
19. Charlton D.E., Allen B.J. Monte Carlo calculations of ion passages through brain endothelial nuclei during boron neutron capture therapy. Int J Radiat Biol 1993, 64:739-747.
20. Tung C.J., Liu C.S., Wang J.P., Chang S.L. calculations of cellular microdosimetry parameters for alpha particles and electrons. Appl Radiat Isot 2004, 61:739-743.
21. Northcliffe L.C., Schilling R.R. range and stopping-power tables for heavy ions. Nucl Data Tab 1970, A7:233-463.
22. stopping powers and ranges for protons and alpha particles 1993, ICRU Report 49, International Commission on Radiation Units and Measurements, Bethesda, MD, USA.
23. Feng B., Tomizawa K., Michiue H., Han X.J., Miyatake S., Matsui H. development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials 2010, 31(14):4139-4145.
24. Feng B., Tomizawa K., Michiue H., Miyatake S., Han X.J., Fujimura A., et al. delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 9:1746-1755.
25. Takahashi A., Matsumoto H., Nagayama K., Kitano M., Hirose S., Tanaka H., et al. evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 2004, 64(24):8839-8845.
26. Kitamatsu M., Kitabatake M., Noutoshi Y., Ohtsuki T. synthesis and properties of peptide dendrimers containing fluorescent and branched amino acids. Biopolymer 2013, 100(1):64-70.
27. Lim Y., Lee E., Lee M. controlled bioactive nanostructures from self-assembly of peptide building blocks. Angew Chem Int Ed 2007, 46:9011-9014.
28. Barth R.F., Coderre J.A., Vicente M.G., Blue T.E. boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005, 11:3987-4002.
29. Henriksson R., Capala J., Michanek A., Lindahl S.A., Salford L.G., Franzén L., et al. boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008, 183-191.
30. Detta A., Cruickshank G.S. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res 2009, 69(5):2126-2132.
31. Oda K., Hosoda N., Endo H., Saito K., Tsujihara K., Yamamura M., et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 2010, 101(1):173-179.
32. Kaira K., Oriuchi N., Otani Y., Shimizu K., Tanaka S., Imai H., et al. fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007, 13(21):6369-6378.
33. Maruyama K., Ishida O., Kasaoka S., Takizawa T., Utoguchi N., Shinohara A., et al. intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 2004, 98(2):195-207.
34. Masunaga S., Kasaoka S., Maruyama K., Nigg D., Sakurai Y., Nagata K., et al. the potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-(10)B (GB-10) as (10)B-carriers for boron neutron capture therapy. Int J Radiat Oncol Biol Phys 2006, 66(5):1515-1522.
35. Lee J.D., Ueno M., Miyajima Y., Nakamura H. synthesis of boron cluster lipids: closo-dodecaborate as an alternative hydrophilic function of boronated liposomes for neutron capture therapy. Org Lett 2007, 9(2):323-326.
36. Nakamura H., Ueda N., Ban H.S., Ueno M., Tachikawa S. design and synthesis of fluorescence-labeled closo-dodecaborate lipid: its liposome formation and in vivo imaging targeting of tumors for boron neutron capture therapy. Org Biomol Chem 2012, 10(7):1374-1380.
37. Noguchi H., Matsushita M., Kobayashi N., Levy M.F., Matsumoto S. recent advances in protein transduction technology. Cell Transplant 2010, 19(6):649-654.
38. Jansen J.F., Debrabandervandenberg E.M., Meijer E.W. encapsulation of guest molecules into a dendritic box. Science 1994, 266:1226-1229.
39. Esfand R., Tomalia D.A. poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today 2001, 6:427-436.
40. Higashi N., Koga T., Niwa M. enantioselective binding and stable encapsulation of alpha-amino aids in a helical poly(L-glutamic acid)-shelled dendrimer in aqueous solutions. ChemBioChem 2002, 3:448-454.
41. Inoue Y., Kurihara R., Tsuchida A., Hasegawa M., Nagashima T., Mori T., et al. efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Release 2008, 126:59-66.
42. Haensler J., Szoka F.C. polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993, 4:372-379.
43. Hardy J.G., Kostiainen M.A., Smith D.K., Gabrielson N.P., Pack D.W. dendrons with spermine surface groups as potential building blocks for nonviral vectors in gene therapy. Bioconjug Chem 2006, 17:172-178.
44. van den Berg A., Dowdy S.F. protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol 2011, 6:888-893.
45. Snyder E.L., Dowdy S.F. recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2005, 1:43-51.
46. Aina O.H., Liu R., Sutcliffe J.L., Marik J., Pan C.X., Lam K.S. from combinatorial chemistry to cancer-targeting peptides. Mol Pharmacol 2007, 4(5):631-651.
47. Yao L., Danniels J., Moshnikova A., Kuznetsov S., Ahmed A., Engelman D.M. pHLIP peptide targets nanogold particles to tumors. Proc Natl Acad Sci U S A 2013, 110(2):465-470.
48. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., Van Meir E.G. hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005, 2:134-153.